We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Compared to Estimates, Labcorp (LH) Q4 Earnings: A Look at Key Metrics (Revised)
Read MoreHide Full Article
Labcorp (LH - Free Report) reported $3.03 billion in revenue for the quarter ended December 2023, an increase of 3.5% from $2.93 billion in the fourth quarter of 2022. EPS of $3.30 for the same period compares to $3.05 a year ago.
The reported revenue compares to the Zacks Consensus Estimate of $3.01 billion, representing a surprise of +0.86%. The company delivered an EPS surprise of +0.30%, with the consensus EPS estimate being $3.29.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Labcorp performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
Net book-to-bill Ratio: 1% versus the two-analyst average estimate of 1.2%.
Ending backlog: 8.25 billion compared to the 12.38 billion average estimate based on two analysts.
Revenues- Biopharma Laboratory Services: $694.80 million compared to the $713.90 million average estimate based on three analysts. The reported number represents an increase of 7.1% year over year.
Revenues- Diagnostics Laboratories: $2.35 billion versus $2.30 billion estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +2.7% change.
Adjusted Operating Income- Biopharma Laboratory Services: $109 million versus the three-analyst average estimate of $110.50 million.
Adjusted Operating Income- Diagnostics Laboratories: $353.70 million compared to the $369.33 million average estimate based on three analysts.
Shares of Labcorp have returned +2.3% over the past month versus the Zacks S&P 500 composite's +4.6% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
(We are reissuing this article to correct a mistake. The original article, issued on February 15, 2024, should no longer be relied upon.)
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Compared to Estimates, Labcorp (LH) Q4 Earnings: A Look at Key Metrics (Revised)
Labcorp (LH - Free Report) reported $3.03 billion in revenue for the quarter ended December 2023, an increase of 3.5% from $2.93 billion in the fourth quarter of 2022. EPS of $3.30 for the same period compares to $3.05 a year ago.
The reported revenue compares to the Zacks Consensus Estimate of $3.01 billion, representing a surprise of +0.86%. The company delivered an EPS surprise of +0.30%, with the consensus EPS estimate being $3.29.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Labcorp performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
View all Key Company Metrics for Labcorp here>>>
Shares of Labcorp have returned +2.3% over the past month versus the Zacks S&P 500 composite's +4.6% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
(We are reissuing this article to correct a mistake. The original article, issued on February 15, 2024, should no longer be relied upon.)